Pieris Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 21.90

PIRS Stock  USD 16.77  0.84  5.27%   
Pieris Pharmaceuticals' future price is the expected price of Pieris Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Pieris Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Pieris Pharmaceuticals Backtesting, Pieris Pharmaceuticals Valuation, Pieris Pharmaceuticals Correlation, Pieris Pharmaceuticals Hype Analysis, Pieris Pharmaceuticals Volatility, Pieris Pharmaceuticals History as well as Pieris Pharmaceuticals Performance.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.
  
Price Earnings To Growth Ratio is likely to gain to 0.02 in 2024, whereas Price To Sales Ratio is likely to drop 0.36 in 2024. Please specify Pieris Pharmaceuticals' target price for which you would like Pieris Pharmaceuticals odds to be computed.

Pieris Pharmaceuticals Target Price Odds to finish over 21.90

The tendency of Pieris Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 21.90  or more in 90 days
 16.77 90 days 21.90 
near 1
Based on a normal probability distribution, the odds of Pieris Pharmaceuticals to move over $ 21.90  or more in 90 days from now is near 1 (This Pieris Pharmaceuticals probability density function shows the probability of Pieris Stock to fall within a particular range of prices over 90 days) . Probability of Pieris Pharmaceuticals price to stay between its current price of $ 16.77  and $ 21.90  at the end of the 90-day period is about 52.31 .
Given the investment horizon of 90 days Pieris Pharmaceuticals has a beta of 0.45 indicating as returns on the market go up, Pieris Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Pieris Pharmaceuticals will be expected to be much smaller as well. Additionally Pieris Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Pieris Pharmaceuticals Price Density   
       Price  

Predictive Modules for Pieris Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pieris Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
13.7615.9318.10
Details
Intrinsic
Valuation
LowRealHigh
11.6413.8115.98
Details
Naive
Forecast
LowNextHigh
13.3715.5417.71
Details
1 Analysts
Consensus
LowTargetHigh
6.377.007.77
Details

Pieris Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Pieris Pharmaceuticals is not an exception. The market had few large corrections towards the Pieris Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pieris Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pieris Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.23
β
Beta against Dow Jones0.45
σ
Overall volatility
0.69
Ir
Information ratio -0.13

Pieris Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pieris Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pieris Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Pieris Pharmaceuticals generated a negative expected return over the last 90 days
Pieris Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M).
Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09.
Latest headline from news.google.com: PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS - Marketscreener.com

Pieris Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pieris Stock often depends not only on the future outlook of the current and potential Pieris Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pieris Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.1 M
Cash And Short Term Investments26.4 M

Pieris Pharmaceuticals Technical Analysis

Pieris Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Pieris Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Pieris Pharmaceuticals. In general, you should focus on analyzing Pieris Stock price patterns and their correlations with different microeconomic environments and drivers.

Pieris Pharmaceuticals Predictive Forecast Models

Pieris Pharmaceuticals' time-series forecasting models is one of many Pieris Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Pieris Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Pieris Pharmaceuticals

Checking the ongoing alerts about Pieris Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Pieris Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Pieris Pharmaceuticals generated a negative expected return over the last 90 days
Pieris Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M).
Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09.
Latest headline from news.google.com: PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS - Marketscreener.com

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.